Decoy Therapeutics Inc. Net Fee Amt
Decoy Therapeutics Inc. (DCOY) had Net Fee Amt of $3.85 thousand as of 2026-07-10, per its S-1 filed 2026-07-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-10
- 2026-07-10: Net Fee Amt $3.85K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-10 | $3.85K S-1 · filed 2026-07-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |